Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors
Introduction: Cyfra 21 is a serum-soluble fragment of cytokeratin19. Increased Cyfra 21 serum levels and their benefit as a tumor marker have been shown in some malignancies. This study aimed to evaluate the serum levels of Cyfra 21 in patients with benign and malignant salivary gland tumors. Materi...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Mashhad University of Medical Sciences
2017-07-01
|
Series: | Iranian Journal of Otorhinolaryngology |
Subjects: | |
Online Access: | http://ijorl.mums.ac.ir/article_8946_9adc07bf5e867394f0862d3701dfd7da.pdf |
id |
doaj-d8430a53329349e2b1a5faee1df54b13 |
---|---|
record_format |
Article |
spelling |
doaj-d8430a53329349e2b1a5faee1df54b132020-11-25T00:52:22ZengMashhad University of Medical SciencesIranian Journal of Otorhinolaryngology2251-72512251-726X2017-07-0129420320810.22038/ijorl.2017.21085.16998946Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland TumorsNaghmeh Jeiroodi0Seyed Mohammad- Javad Aslani1Bijan Khademi2Mahyar Malekzadeh3Zohreh Jaafari- Ashkavandi4Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.Otolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.Institute of Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.Introduction: Cyfra 21 is a serum-soluble fragment of cytokeratin19. Increased Cyfra 21 serum levels and their benefit as a tumor marker have been shown in some malignancies. This study aimed to evaluate the serum levels of Cyfra 21 in patients with benign and malignant salivary gland tumors. Materials and Methods: In this cross-sectional study, the serum level of Cyfra 21 in 44 patients with malignant salivary gland tumors and 16 cases of pleomorphic adenoma were compared with 28 healthy controls using enzyme-linked immunosorbent assay (ELISA). Data were analyzed statistically using the Kruskal Wallis test, analysis of variance (ANOVA) and Spearman’s correlation tests. Results: Mean serum levels of Cyfra 21 were 0.135 ± 0.285 ng/ ml in the control group, 0.167 ± 0.142 ng/ ml in patients with pleomorphic adenoma and 1.059 ± 3.251 ng/ml in patients with malignant salivary gland tumors. There was no significant difference among groups. Cyfra 21 levels did not correlate with location of tumor, clinical stage or cigarette smoking. Conclusion: Results of the present study showed no significant difference in Cyfra 21 serum level in salivary gland tumors compared with normal individuals. In addition, Cyfra 21 serum level was not sufficiently sensitive to function as a tumor marker in salivary gland tumors.http://ijorl.mums.ac.ir/article_8946_9adc07bf5e867394f0862d3701dfd7da.pdfAdenoid cystic carcinomaCyfra 21Mucoepidermoid carcinomaPleomorphic adenomaSerumsalivary gland |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Naghmeh Jeiroodi Seyed Mohammad- Javad Aslani Bijan Khademi Mahyar Malekzadeh Zohreh Jaafari- Ashkavandi |
spellingShingle |
Naghmeh Jeiroodi Seyed Mohammad- Javad Aslani Bijan Khademi Mahyar Malekzadeh Zohreh Jaafari- Ashkavandi Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors Iranian Journal of Otorhinolaryngology Adenoid cystic carcinoma Cyfra 21 Mucoepidermoid carcinoma Pleomorphic adenoma Serum salivary gland |
author_facet |
Naghmeh Jeiroodi Seyed Mohammad- Javad Aslani Bijan Khademi Mahyar Malekzadeh Zohreh Jaafari- Ashkavandi |
author_sort |
Naghmeh Jeiroodi |
title |
Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors |
title_short |
Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors |
title_full |
Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors |
title_fullStr |
Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors |
title_full_unstemmed |
Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors |
title_sort |
serum levels of cyfra 21 in patients with benign and malignant salivary gland tumors |
publisher |
Mashhad University of Medical Sciences |
series |
Iranian Journal of Otorhinolaryngology |
issn |
2251-7251 2251-726X |
publishDate |
2017-07-01 |
description |
Introduction: Cyfra 21 is a serum-soluble fragment of cytokeratin19. Increased Cyfra 21 serum levels and their benefit as a tumor marker have been shown in some malignancies. This study aimed to evaluate the serum levels of Cyfra 21 in patients with benign and malignant salivary gland tumors. Materials and Methods: In this cross-sectional study, the serum level of Cyfra 21 in 44 patients with malignant salivary gland tumors and 16 cases of pleomorphic adenoma were compared with 28 healthy controls using enzyme-linked immunosorbent assay (ELISA). Data were analyzed statistically using the Kruskal Wallis test, analysis of variance (ANOVA) and Spearman’s correlation tests. Results: Mean serum levels of Cyfra 21 were 0.135 ± 0.285 ng/ ml in the control group, 0.167 ± 0.142 ng/ ml in patients with pleomorphic adenoma and 1.059 ± 3.251 ng/ml in patients with malignant salivary gland tumors. There was no significant difference among groups. Cyfra 21 levels did not correlate with location of tumor, clinical stage or cigarette smoking. Conclusion: Results of the present study showed no significant difference in Cyfra 21 serum level in salivary gland tumors compared with normal individuals. In addition, Cyfra 21 serum level was not sufficiently sensitive to function as a tumor marker in salivary gland tumors. |
topic |
Adenoid cystic carcinoma Cyfra 21 Mucoepidermoid carcinoma Pleomorphic adenoma Serum salivary gland |
url |
http://ijorl.mums.ac.ir/article_8946_9adc07bf5e867394f0862d3701dfd7da.pdf |
work_keys_str_mv |
AT naghmehjeiroodi serumlevelsofcyfra21inpatientswithbenignandmalignantsalivaryglandtumors AT seyedmohammadjavadaslani serumlevelsofcyfra21inpatientswithbenignandmalignantsalivaryglandtumors AT bijankhademi serumlevelsofcyfra21inpatientswithbenignandmalignantsalivaryglandtumors AT mahyarmalekzadeh serumlevelsofcyfra21inpatientswithbenignandmalignantsalivaryglandtumors AT zohrehjaafariashkavandi serumlevelsofcyfra21inpatientswithbenignandmalignantsalivaryglandtumors |
_version_ |
1725242743357177856 |